• videocam Live Webinar with Live Q&A
  • calendar_month January 26, 2027 @ 1:00 PM ET/10:00 AM PT
  • signal_cellular_alt Intermediate
  • card_travel Litigation
  • schedule 90 minutes

Complex Products Cases: Excluding Epidemiological Evidence Under FRE 702 and Impact of Acetaminophen-Autism Cases

Distinguishing Unreliable Methodologies From Validly Disputed Scientific Studies and the Limits of Judicial Gatekeeping

About the Course

Introduction

This CLE webinar will discuss how defendants in complex product liability cases can persuade a court that an epidemiologist's studies and opinions are not merely subject to valid scientific dispute but are the result of unreliable methodology and should be inadmissible under Federal Rule of Evidence 702 and Daubert. The panel will also help counsel identify and apply the lessons from the Second Circuit's decision in the Acetaminophen-Autism cases about the limits of a trial court's gatekeeping discretion.

Description

In every toxic tort, medical device, and pharmaceutical product liability case, a threshold issue is general causation—whether the product, device, or substance is even capable of causing the alleged harm in some part of the population. Epidemiological experts and research are the "gold standard" of general causation evidence. If defendants can get the plaintiff's epidemiological testimony and related studies excluded under Federal Rule of Evidence 702 and Daubert, the case will likely end.

Courts are increasingly taking a "hard look" at experts' methodologies and assessing whether the expert's opinion reflects a reliable application of the principles and methods to the facts of the case. For example, courts are analyzing experts' logic, asking if their final opinions exceed the limits of applicable studies, and being sensitive to when experts are "cherry-picking" the evidence to fit the desired conclusions. 

Courts cannot, however, substitute their judgment to decide scientific disputes. Yet the line between rigorous scrutiny and abuse of discretion, between gatekeeper and decision-maker, is often blurry. The task of counsel is to bring that boundary into sharper focus for clients, courts, and ultimately the jury.

Listen as this esteemed panel of product liability litigators discusses the admissibility of epidemiological evidence in toxic tort, medical device, and pharmaceutical product liability cases.

Presented By

Christopher G. Campbell
Partner
DLA Piper

Mr. Campbell is the Chair of DLA Piper's Product Liability and Mass Tort practice group, awarded "Practice Group of the Year" in 2025 by Law360, ranked Band 1 by Chambers, and ranked Tier 1 by The Legal 500. He is also Co-Chair of the Product Liability, Mass Torts & Class Actions group. A graduate of Harvard Law School, Mr. Campbell has 25 years' experience in all phases of mass tort, class action, and other product liability complex commercial litigation, serving as global, national, and trial counsel for many global companies across industries. He also advises clients on regulatory, communications, and other strategic matters that impact the clients' business interests or reputations. Forbes recently recognized Mr. Campbell as "best in state" in Georgia, the only product liability lawyer to receive this recognition in the state. He regularly speaks and writes on the topics of product liability, mass torts, and class action litigation, as well as the attorney-client privilege, expert witnesses, pharmacovigilance, trial tactics, and other topics. Mr. Campbell is the co-author of the book, Expert Witnesses in Product Liability Cases.

Allie Ozurovich
Partner
Dechert LLP

Ms. Ozurovich is a partner in the firm’s product liability and mass torts practice group. She focuses her practice on complex commercial litigation matters, with an emphasis on representing major consumer products manufacturers and pharmaceutical companies in federal multidistrict litigation and coordinated state court proceedings involving claims of personal injury, wrongful death, and consumer fraud. Ms. Ozurovich also regularly represents emerging companies, healthcare organizations, and app developers in consumer privacy and data breach litigation brought by private litigants and government agencies. In 2025, she was recognized by Legal 500 US for Dispute Resolution: Product Liability, Mass Tort and Class Action – Defense: Toxic Tort. In 2026, Ms. Ozurovich was named to the Daily Journal’s “Top 40 Under 40” list.

Credit Information
  • This 90-minute webinar is eligible in most states for 1.5 CLE credits.


  • Live Online


    On Demand

Date + Time

  • event

    Tuesday, January 26, 2027

  • schedule

    1:00 PM ET/10:00 AM PT

I. General, specific, and legal causation 

A. Role of differential diagnosis

II. Science of epidemiology and the hierarchy of evidence

III. Association vs. causation 

A. Bradford Hill criteria

B. International Agency for Research on Cancer (IARC)

IV. Assessing admissibility under FRE 702 

A. Assist trier of fact

B. Sufficient facts or data

C. Product of reliable principles and methods

D. Expert has reliably applied the principles and methods to the facts of the case

E. Daubert criteria for scientific evidence

V. Strategies for plaintiffs and defendants after the Acetaminophen-Autism cases

The panel will discuss these and other key issues:

  • What did the Acetaminophen-Autism cases say about the limits of a trial court's gatekeeping discretion?
  • Is there a "test" for determining when a court has substituted its judgment about causation?
  • When considering admissibility, must rebuttal expert evidence meet the same standards as the plaintiff's evidence?
  • What factors show that an expert's opinion does not reflect a reliable application of the principles and methods to the facts of the case?